Abstract
Abstract Infrequently documented, drug-resistant tuberculous meningitis presents diagnostic and treatment challenges, particularly during SARS-CoV-2 coinfection. Timely identification is crucial to prevent severe complications, yet the optimal treatment course remains uncertain, marked by elevated morbidity and mortality rates. Standard guidelines recommend at least four potent secondline anti-TB drugs. Amid a pandemic, it’s vital not to solely focus on COVID-19 but to explore various aspects. This case outlines a 20-year-old with multi-drug-resistant tuberculous meningitis and SARS-CoV-2, in contact with an MDR pulmonary tuberculosis case. Diagnosis involved molecular and bacteriological cerebrospinal fluid examinations. GeneXpert MTB/RIF revealed rifampicin resistance, and subsequent testing indicated TB resistance to multiple drugs. Tuberculous meningitis, a predominant manifestation, demands careful attention for accurate diagnosis and strategic management. The judicious selection and duration of efficacious drugs are pivotal in treating MDR tuberculous meningitis.
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
